<DOC>
	<DOCNO>NCT00826748</DOCNO>
	<brief_summary>The purpose study assess effect inhale beclomethasone ( inhaled corticosteroid ) pattern lung airway epithelium alveolar macrophage gene expression healthy smoker . We hypothesize administration beclomethasone result reversibility airway epithelium alveolar macrophage gene expression change induce cigarette smoking .</brief_summary>
	<brief_title>Effect Inhaled Steroids Gene Expression Lungs - 2</brief_title>
	<detailed_description>The study involve healthy smoker non smoker enrol IRB approve protocol # 0005004439 entitle `` Evaluation Lungs Normal ( Smokers , Ex-smokers , Non-Smokers ) Individuals Segmental Bronchopulmonary Lung Lavage , Bronchial Brushing , Bronchial Wall Biopsy '' . They invite participate protocol meet additional inclusion/exclusion criterion protocol ( see inclusion/exclusion criterion , section A6 ) . The Principal Investigator , Ann E. Tilley , MD authorize representative obtain consent individual study . Once enrol , smoker randomize either Group A [ 320 microgram ( mcg ) beclomethasone ; 2 puff twice day ( puff delivers 80 mcg ) 7 day ] Group B ( treatment ) . Beclomethasone available meter dose inhaler [ QVAR ( TEVA Pharmaceuticals ) ] deliver 80 microgram ( mcg ) beclomethasone per one puff . We use QVAR HFA ( TEVA Pharmaceuticals ) , deliver 80 mcg per puff . QVAR purchase Department Genetic Medicine . It dispense appropriate research subject recruit trial Department Genetic Medicine 1305 York Ave YAB-13th floor , New York , NY 10021 ( facility Weill Medical College ) . It store The Arthur &amp; Rochelle Belfer Gene Therapy Core Facility locate 515 E. 71st St. , S901 , New York , NY 10021 supervision Stephen Kaminksy , PhD , Co-Director GMP ( Good Manufacturing Practice ) . Each study individual receive 1 package study medication consist 1 canister QVAR 80 MDI ( meter dose inhaler ) . Non-smokers , define individual never smoke , part Group C. Group C act control like Group B receive treatment . For Group A , Group B Group C participant , screening , baseline bronchoscopy , bronchoscopies Days 7±3 14±3 test perform part IRB approve protocol # 0005004439 . No additional bronchoscopies perform current protocol .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Group A B All study individual enrol WeillIRB protocol # 0005004439 entitle `` Evaluation Lungs Normal ( Smokers , Exsmokers , NonSmokers ) Individuals Segmental Bronchopulmonary Lung Lavage , Bronchial Brushing , Bronchial Wall Biopsy '' All study subject able provide inform consent Current smoker 15to 40 packyear history All study individual healthy per protocol # 0005004439 entitle `` Evaluation Lungs Normal ( Smokers , Exsmokers , NonSmokers ) Individuals Segmental Bronchopulmonary Lung Lavage , Bronchial Brushing , Bronchial Wall Biopsy '' Group C All study individual enrol WeillIRB protocol # 0005004439 entitle `` Evaluation Lungs Normal ( Smokers , Exsmokers , NonSmokers ) Individuals Segmental Bronchopulmonary Lung Lavage , Bronchial Brushing , Bronchial Wall Biopsy '' All study subject able provide inform consent All study individual healthy per protocol # 0005004439 entitle `` Evaluation Lungs Normal ( Smokers , Exsmokers , NonSmokers ) Individuals Segmental Bronchopulmonary Lung Lavage , Bronchial Brushing , Bronchial Wall Biopsy '' Group A B Smokers intend quit smoke next 14 day . Individuals already receive lung relate inhaler Females pregnant nursing Group C Nonsmokers intend start smoke next 14 day Individuals already receive lung relate inhaler Females pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>inhaled steroid</keyword>
	<keyword>gene expression</keyword>
	<keyword>smoker 's lung</keyword>
</DOC>